Formulation Development of Diclofenac Sodium Emulgel Using Aloe vera Gel for Transdermal Drug Delivery System



  • Thanushree H.R.
  • Kiran Kumar G B
  • Ankit Acharya


Diclofenac sodium has many side effects like nausea, vomiting, GIT disorders. These side effects can be reduced by converting into emulgel formulations. The emulgel formulation of Diclofenac Sodium was prepared by incorporation method, using span 20 and tween 20 as non-ionic surfactants, clove oil and cinnamon oil as penetration enhancers, Aloe vera as a gel base and sesame oil as a solvent. The prepared emulgel formulations were evaluated for compatibility study, physical examination, viscosity, spreadability, in vitro diffusion studies, various release kinetic studies and stability studies. In vitro diffusion studies were carried out using cellophane membrane, results showed that emulgel formulations (F2-F7) showed higher cumulative percent drug release (49-65%) compared to normal gel (48%) and marketed gel (35%). Results of in vitro diffusion studies showed that formulation F3 and F6 exhibited 64% and 65% drug release respectively over a period of 6 hrs. In conclusion, a physiochemical stable diclofenac emulgel was formulated, which could deliver significant amount of drug across the skin in steady-state manner for the prolong period of time in the treatment of osteoarthritis.


Download data is not yet available.


Metrics Loading ...


Diclofenac Sodium, Emulgel, Aloe vera, Osteoarthritis




How to Cite

H.R. T, G B KK, Acharya A. Formulation Development of Diclofenac Sodium Emulgel Using Aloe vera Gel for Transdermal Drug Delivery System. Scopus Indexed [Internet]. 2017 Sep. 30 [cited 2024 Apr. 21];10(5):3858-65. Available from:



Research Articles


Ahuja N, Saini V, Bishnoi VK, Garg A, Hisoria M, Sharma J, and Nepali K. (2008) Formulation and evaluation of Diclofenac sodium gel by using natural polymer. Rasayan J Chem. 1(3): 564-6.
Barry BW (2001). Novel mechanisms and devices to enable successful transdermal drug delivery. Eur J Pharma Sci. 14: 101-14.
Batlouni M (2010). Nonsteroidal anti-inflammatory drugs: Cardiovascular, cerebrovascular and renal effects. Arq Bras Cardiol. 94(4): 522-9.
Cleary GW, and Beskar E. (2003). Transdermal and transdermal like delivery system opportunities. Today and the future. Pharm Tech. 82-08.
Devi AS, Pinnika A, and Divya P. (2014) Formulation and evaluation of candesartan cilexetil transdermal proniosomal gel. J Drug Del. 4(2): 90-98.
Hiligsmann M, Copper C, Guillemin F, and Hochberg MC (2014). Seminars in arthritis and rheumatism. Science direct. 44(3): 271-82.
Kumar V, Mahant S, Rao R, and Nanda S (2014). Emulgelbased topical delivery system for loratadine. Int J Pharm Sci. 2(4): 254-71.
Mohaamed MI (2004). Optimization of Chlorphenesin emulgel formulation. AAPS J. 6(3): 26.
Mohammed HKP, Easo S, Hafsa PV, Mohanta GP, and Nayar C (2013). Emulgel: An advanced review. J Pharm Scl Res. 5(12): 254-58.
Nikalje AP, and Tiwari S (2012). Ethosomes: A novel tool for transdermal drug delivery. Int J Res Pharm Sci. 2(1): 1-20.